14 research outputs found
Drag reduction on a three-dimensional blunt body with different rear cavities under cross-wind conditions
Experimental study on the effect of adaptive flaps on the aerodynamics of an Ahmed body
We perform an experimental study on the turbulent flow around a square-back Ahmed body of height, h, at varying Re=u∞h/ν∈[0.5,1]×105, where u∞ is the free-stream velocity and ν is the incoming flow kinematic viscosity, under different yaw angles β=(0∘,-5∘,-10∘), to analyze the use of rear flexibly hinged parallel plates as a control strategy to reduce the drag in a self-adaptive manner under changing flow conditions. The model implements rear parallel rigid flaps of depth d=0.5h, which are mounted with torsional joints through embedded flexible foils of calibrated thickness. This holding system restricts the motion of the plates to a rotary displacement, θ. The fluid-structure dynamics is characterized by the reduced velocity, defined as U∗=u∞/fnh, where fn is the natural frequency of rotary oscillations of the hinged plates, measured in free-decay tests of flaps. In fact, we have explored the range of reduced velocity, U∗=[0,65], varying u∞ and consequently Re. We perform force and pressure measurements to quantify the variations of the drag and the base pressure coefficients while laser displacement sensors are used to obtain the angular flaps motion. Results show that the hinged plates decrease the drag coefficient of the original body by nearly 4.4% for flow conditions aligned with the body axis. Under cross-flow conditions, their efficiency is even larger, attaining relative reductions drag of nearly 9.1% at β=-10∘ (13.5% in comparison with a body with fixed rigid plates of the same depth). Such variations are shown to be associated with a passive reconfiguration process of rear flaps. Additionally, hinged flaps are shown to interact with the reflectional-symmetry-breaking (RSB) modes, typically present in the wake of three-dimensional bodies. At aligned conditions, the interaction with the RSB modes is characterized by two regimes, in such a way that the hinged flaps manage to partially stabilize the RSB modes, and consequently to inhibit the bistable behavior at low values of U∗ (in a similar manner to rigid flaps), while at high values of U∗, they respond dynamically to switches between the opposite wake deflections of the RSB modes, deviating themselves accordingly
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.
Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).
Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001).
Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio
Registro Español de Trasplante Cardiaco. XXXI Informe Oficial de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología
Introducción y objetivos
Se presentan las características clínicas y los resultados de los trasplantes cardiacos realizados en España con la actualización correspondiente a 2019.
Métodos
Se describen las características clínicas y los resultados de los trasplantes cardiacos realizados en 2019, así como las tendencias de estos en el periodo 2010-2018.
Resultados
En 2019 se realizaron 300 trasplantes (8.794 desde 1984; 2.745 entre 2010 y 2019). Respecto a años previos, los cambios más llamativos son el descenso hasta el 38% de los trasplantes realizados en código urgente, y la consolidación en el cambio de asistencia circulatoria pretrasplante, con la práctica desaparición del balón de contrapulsación (0, 7%), la estabilización del uso del oxigenador extracorpóreo de membrana (9, 6%) y el aumento de los dispositivos de asistencia ventricular (29%). La supervivencia en el trienio 2016-2018 es similar a la del trienio 2013-2015 (p = 0, 34), y ambas mejores que la del trienio 2010-2012 (p = 0, 002 y p = 0, 01 respectivamente).
Conclusiones
Se mantienen estables tanto la actividad del trasplante cardiaco en España como los resultados en supervivencia en los últimos 2 trienios. Hay una tendencia a realizar menos trasplantes urgentes, la mayoría con dispositivos de asistencia ventricular.
Introduction and objectives: The present report describes the clinical characteristics and outcomes of heart transplants in Spain and updates the data to 2019.
Methods: We describe the clinical characteristics and outcomes of heart transplants performed in Spain in 2019, as well as trends in this procedure from 2010 to 2018.
Results: In 2019, 300 transplants were performed (8794 since 1984; 2745 between 2010 and 2019). Compared with previous years, the most notable findings were the decreasing rate of urgent transplants (38%), and the consolidation of the type of circulatory support prior to transplant, with an almost complete disappearance of counterpulsation balloon (0.7%), stabilization in the use of extracorporeal membrane oxygenation (9.6%), and an increase in the use of ventricular assist devices (29.0%). Survival from 2016 to 2018 was similar to that from 2013 to 2015 (P = .34). Survival in both these periods was better than that from 2010 to 2012 (P = .002 and P = .01, respectively).
Conclusions: Heart transplant activity has remained stable during the last few years, as have outcomes (in terms of survival). There has been a trend to a lower rate of urgent transplants and to a higher use of ventricular assist devices prior to transplant